Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does PEXIDARTINIB Cause Alanine aminotransferase increased? 124 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 124 reports of Alanine aminotransferase increased have been filed in association with PEXIDARTINIB (Turalio). This represents 12.8% of all adverse event reports for PEXIDARTINIB.

124
Reports of Alanine aminotransferase increased with PEXIDARTINIB
12.8%
of all PEXIDARTINIB reports
1
Deaths
20
Hospitalizations

How Dangerous Is Alanine aminotransferase increased From PEXIDARTINIB?

Of the 124 reports, 1 (0.8%) resulted in death, 20 (16.1%) required hospitalization.

Is Alanine aminotransferase increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for PEXIDARTINIB. However, 124 reports have been filed with the FAERS database.

What Other Side Effects Does PEXIDARTINIB Cause?

Fatigue (378) Product dose omission issue (335) Hair colour changes (327) Nausea (213) Pruritus (186) Aspartate aminotransferase increased (134) Rash (131) Off label use (130) Diarrhoea (106) Headache (103)

What Other Drugs Cause Alanine aminotransferase increased?

METHOTREXATE (2,440) RITUXIMAB (1,651) ADALIMUMAB (1,308) TOCILIZUMAB (1,163) ETANERCEPT (1,131) LEFLUNOMIDE (1,099) ACETAMINOPHEN (1,083) REMDESIVIR (1,047) FINGOLIMOD (1,020) INFLIXIMAB (981)

Which PEXIDARTINIB Alternatives Have Lower Alanine aminotransferase increased Risk?

PEXIDARTINIB vs PHENACETIN PEXIDARTINIB vs PHENAZOPYRIDINE PEXIDARTINIB vs PHENCYCLIDINE PEXIDARTINIB vs PHENELZINE PEXIDARTINIB vs PHENOBARBITAL

Related Pages

PEXIDARTINIB Full Profile All Alanine aminotransferase increased Reports All Drugs Causing Alanine aminotransferase increased PEXIDARTINIB Demographics